

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, May 18, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L7	ILKAP	4
<input type="checkbox"/>	L6	lorens-james-\$.in.	5
<input type="checkbox"/>	L5	bogenberger-jakob.in.	3
<input type="checkbox"/>	L4	atchison-robert.in.	0
<input type="checkbox"/>	L3	L1 and angiogenesis	4
<input type="checkbox"/>	L2	L1 and ilkap	0
<input type="checkbox"/>	L1	lorens-james.in.	18

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 09:34:05 ON 18 MAY 2004)

FILE '1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX, COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, OCEAN, MEDICONF, PASCAL, PAPERCHEM2, POLLUAB, SOLIDSTATE' ENTERED AT 09:36:40 ON 18 MAY 2004

FILE 'DISSABS, 1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX, COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, OCEAN, MEDICONF, PASCAL, PAPERCHEM2, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOCOMMERCE, ...' ENTERED AT 09:37:44 ON 18 MAY 2004

L1	3 S ILKAP (S) ENDOTHELIAL
L2	23 S ILKAP (S) INTEGRIN
L3	8 DUP REM L2 (15 DUPLICATES REMOVED)
L4	7 S ILKAP (S) ANGIOGEN?

=> d ibib ab 1-3

L1 ANSWER 1 OF 3 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN

ACCESSION NUMBER: 2003-09118 BIOTECHDS

TITLE: Identifying a compound that modulates angiogenesis, useful for monitoring changes in cell surface marker expression or avb3 integrin production, comprises contacting the compound with an integrin-linked kinase associated protein; drug screening by vector-mediated gene transfer and expression in host cell useful for gene therapy

AUTHOR: LORENS J B; XU W; ATCHISON R E; BOGENBERGER J

PATENT ASSIGNEE: RIGEL PHARM INC

PATENT INFO: US 2002156003 24 Oct 2002

APPLICATION INFO: US 2001-935124 21 Aug 2001

PRIORITY INFO: US 2001-935124 21 Aug 2001; US 2001-284760 18 Apr 2001

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2003-182647 [18]

AB DERWENT ABSTRACT:

NOVELTY - Identifying a compound that modulates angiogenesis comprising contacting the compound with an integrin-linked kinase associated protein (**ILKAP**) polypeptide, and determining the functional effect of the compound on the **ILKAP** polypeptide, is new.

DETAILED DESCRIPTION - Identifying a compound that modulates angiogenesis comprising: (a) contacting the compound with an integrin-linked kinase associated protein (**ILKAP**) polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid encoding a sequence of 393 amino acids (I) given in the specification; and (b) determining the functional effect of the compound on the **ILKAP** polypeptide. An INDEPENDENT CLAIM is also included for a method of modulating angiogenesis in a subject by administering to the subject a compound identified from the novel method, an **ILKAP** polypeptide or a nucleic acid encoding the **ILKAP** polypeptide.

BIOTECHNOLOGY - Preferred Method: The functional effect is determined in vitro, by measuring the ligand binding to the polypeptide, by measuring phosphatase activity of the polypeptide, or by measuring the avb3 expression, or haptotaxis. The functional effect is a physical effect, a chemical effect or a phenotypic effect. The polypeptide is expressed in a eukaryotic host cell, where the host cell is an **endothelial** cell. The polypeptide may also be a recombinant or comprises the sequence (I). The compound is an antisense molecule or a small organic molecule. The compound may also be an antibody and inhibits angiogenesis.

ACTIVITY - None given.

MECHANISM OF ACTION - Integrin-linked Kinase Associated Protein Modulator; Gene therapy.

USE - The method is useful for identifying modulators of angiogenesis, and for monitoring changes in cell surface marker expression, avb3 integrin production, proliferation and differentiation using either cell lines or primary cells. The compounds identified may be used as conventional lead compound or as potential or actual therapeutics.

ADMINISTRATION - Dosage is 1-100 micro-g for a typical 70 kg patient. Administration can be parenteral (e.g. intraarticular, intravenous, intramuscular, intradermal, intraperitoneal or subcutaneous), oral, inhalation, transdermal, rectal or topical.

EXAMPLE - The integrin-linked kinase associated protein (**ILKAP**) sequence was tested in angiogenesis assays and demonstrated to exert a negative effect on avb3 surface expression. **ILKAP**-expressing **endothelial** cells were assayed for migration towards an ECM component (haptotaxis). The **ILKAP**-expression cells were strongly inhibited in their haptotactic response, an indicator of an anti-angiogenic phenotype. The **ILKAP** nucleic

acid and encoded protein thus represents a drug target for anti-angiogenic therapies. (20 pages)

L1 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:814830 CAPLUS
DOCUMENT NUMBER: 137:321374
TITLE: Use of integrin-linked kinase associated protein in regulation of angiogenesis
INVENTOR(S): Lorens, James B.; Xu, Weiduan; Atchison, Robert E.; Bogenberger, Jakob
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156003	A1	20021024	US 2001-935124	20010821
WO 2002085289	A2	20021031	WO 2002-US12341	20020418
WO 2002085289	A3	20030515		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-284760P P 20010418
US 2001-935124 A 20010821

AB The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase-associated serine/threonine phosphatase 2C ("ILKAP") and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic mols., antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compns. in diagnosis and therapy of angiogenesis.

L1 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2002:280558 USPATFULL
TITLE: Modulators of angiogenesis
INVENTOR(S): Lorens, James B., Portola Valley, CA, UNITED STATES
Xu, Weiduan, San Francisco, CA, UNITED STATES
Atchison, Robert E., San Francisco, CA, UNITED STATES
Bogenberger, Jakob, San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Incorporated, South San Francisco, CA, UNITED STATES, 94080 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156003	A1	20021024
APPLICATION INFO.:	US 2001-935124	A1	20010821 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284760P	20010418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1996

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein ("ILKAP") and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.

=>

LOCUS (LOC): AY024365 GenBank (R)
GenBank ACC. NO. (GBN): AY024365
GenBank VERSION (VER): AY024365.1 GI:13432041
CAS REGISTRY NO. (RN): 328895-62-1
SEQUENCE LENGTH (SQL): 1422
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Primates
DATE (DATE): 22 Mar 2001
DEFINITION (DEF): Homo sapiens integrin-linked kinase-associated
serine/threonine phosphatase 2C mRNA, complete cds.
SOURCE:
ORGANISM (ORGN): Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo
NUCLEIC ACID COUNT (NA): 343 a 348 c 411 g 320 t
REFERENCE: 1 (bases 1 to 1422)
AUTHOR (AU): Leung-Hagesteijn,C.; Mahendra,A.; Naruszewicz,I.;
Hannigan,G.E.
TITLE (TI): Modulation of **integrin** signal transduction by
ILKAP, a protein phosphatase 2C associating
with the **integrin**-linked kinase, ILK1
JOURNAL (SO): EMBO J., 20 (9), 2160-2170 (2001)
OTHER SOURCE (OS): CA 135:328611
REFERENCE: 2 (bases 1 to 1422)
AUTHOR (AU): Leung-Hagesteijn,C.; Hannigan,G.E.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (25-JAN-2001) Research Institute, Hospital
for Sick Children, 555 University Avenue, Toronto, ON
M5G 1X8, Canada

ANSWER 2 OF 8 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN

AN 2003-09118 BIOTECHDS

TI Identifying a compound that modulates angiogenesis, useful for monitoring changes in cell surface marker expression or avb3 integrin production, comprises contacting the compound with an integrin-linked kinase associated protein;
drug screening by vector-mediated gene transfer and expression in host cell useful for gene therapy

AU LORENS J B; XU W; ATCHISON R E; BOGENBERGER J

PA RIGEL PHARM INC

PI US 2002156003 24 Oct 2002

AI US 2001-935124 21 Aug 2001

PRAI US 2001-935124 21 Aug 2001; US 2001-284760 18 Apr 2001

DT Patent

LA English

OS WPI: 2003-182647 [18]